The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers.
Hiu TangSanat KulkarniChristina PetersJasper EddisonMaryam Al-AniSrinivasan MadhusudanPublished in: International journal of molecular sciences (2023)
Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has generated hope for patients. The clinical use of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA germ-line-deficient and/or platinum-sensitive epithelial ovarian cancers has improved survival. However, the emergence of resistance is an ongoing clinical challenge. Here, we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in epithelial ovarian cancers.
Keyphrases
- dna repair
- dna damage
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- current status
- dna damage response
- prognostic factors
- peritoneal dialysis
- palliative care
- minimally invasive
- radiation therapy
- squamous cell carcinoma
- locally advanced
- coronary artery bypass
- cancer therapy
- patient reported
- atrial fibrillation
- childhood cancer